Wedbush initiated coverage on shares of Infinity Pharmaceuticals (NASDAQ:INFI) in a research note issued on Monday, TheFlyOnTheWall.com reports. The firm set an “underperform” rating and a $10.00 price target on the stock. Wedbush’s price objective suggests a potential downside of 32.02% from the company’s current price. Infinity Pharmaceuticals Inc. (NASDAQ:INFI) shares after opening at $11.34 moved to $11.38 on last trade day and at the end of the day closed at $10.95. Company price to cash ratio as 2.47. Infinity Pharmaceuticals Inc. (NASDAQ:INFI) showed a negative weekly performance of -14.79%.
Onconova Therapeutics Inc. (NASDAQ:ONTX) net losses were $62.6 million, $29.9 million and $26.3 million for the years ended December 31, 2013, 2012 and 2011, respectively. We recognized revenues of $4.8 million, $46.2 million and $1.5 million for the years ended December 31, 2013, 2012 and 2011, respectively. Onconova Therapeutics Inc. (NASDAQ:ONTX) shares fell -2.10% in last trading session and ended the day on $6.06. ONTX return on equity ratio is recorded as 113.70% and its return on assets is -114.60%.
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, on 2 April announced the appointment of Pankaj Bhargava, M.D. as Chief Medical Officer. Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) shares moved down -6.78% in last trading session and was closed at $23.50, while trading in range of $23.36 – $25.72. Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) year to date (YTD) performance is -45.85%.
Orbit International Corp. (NASDAQ:ORBT) sales decreased by 15.6% and recorded a net loss of $2,570,000 as compared to a net loss of $135,000 in the prior year period. Orbit International Corp. (NASDAQ:ORBT) weekly performance is -2.06%. On last trading day company shares ended up $2.85. Orbit International Corp. (NASDAQ:ORBT) distance from 50-day simple moving average (SMA50) is -12.81%. Analysts mean target price for the company is $4.50.